Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients

Clinical Transplantation

Volumn 21, Issue 1, 2007, Pages 18-23

  Hummel, Manfred ^a   Yonan, N ^ac   Ross, H ^c   Miller, L W ^u   Sechaud, Romain ^e   Balez, Sebastien ^e   Koelle, Ernst Ulrich ^e   Gerosa, G ^f   Aaronson, K ^g   Ahualli, L ^h   Almenar, L ⁱ   Arizon, J M ^j   Arpesella, G ^k   Crespo, M G ^l   David, S F ^m   Butler, J ^m   Dengler, T ⁿ   Egan, J ^o   Eisen, H J ^p   Haddad, J ^q   Davies, R ^q   Keogh, A M ^r   Kobashigawa, J ^s   Lehmkuhl, H B ^a   Hetzer, R ^a   Livi, U ^t   Modry, D ^v   Burton, J ^v   Mullen, G M ^w   Pisani, B ^w   Murday, A J ^x   Renlund, D G ^y   Segovia, J ^z   Alonso Pulpon, L ^z   Perrone, S ^aa   Vigano, M ^ab   Zucker, M J ^ad   more..

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b Cardiothoracic Transplant Centre   (United Kingdom)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l HOSPITAL JUAN CANALEJO   (Spain)

^m Vanderbilt University Transplant Center   (United States)

ⁿ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^o MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^p TEMPLE UNIVERSITY   (United States)

^q UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^r ST VINCENT S HOSPITAL   (Australia)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t Azienda Osp Udine   (Italy)

^u UNIVERSITY OF MINNESOTA   (United States)

^v UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^w LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^x Scottish Cardiopulmonary Transplant Unit   (United Kingdom)

^y UNIVERSITY OF UTAH   (United States)

^z HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^aa HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^ab FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ac Cardiothoraxic Transplant Centre   (United Kingdom)

^ad NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

Enteric coated mycophenolate sodium; Heart transplantation; Mycophenolate mofetil; Myfortic ; Pharmacokinetics; Variability

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STEADY STATE;

EID: 33846669548     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00569.x     Document Type: Article

References (21)

1. Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
2. Budde K, Glander P, Diekmann F et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004: 5: 1333.
3. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004: 4: 237.
4. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
5. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation (in press).
6. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998: 66: 507.
7. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil. Drug Saf 2001: 24: 645.
8. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005: 80 (Suppl. 2): S235.
9. De Nofrio D, Loh E, Kao A et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant 2000: 19: 1071.
10. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit 2001: 23: 305.
11. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998: 34: 429.
12. Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998: 64: 672.
13. Pisupati J, Jain A, Burckart G et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005: 45: 34.
14. Elfstrom J. Drug pharmacokinetics in the postoperative period. Clin Pharmacokinet 1979: 4: 16.
15. Atcheson BA, Taylor PJ, Kirkpatrick CM et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004: 26: 284.
16. Armstrong VW, Tenderich G, Shipkova M et al. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 2005: 27: 315.
17. Johnson AG, Rigby RJ, Taylor PJ et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999: 66: 492.
18. Mourad M, Malaise J, Chaib Eddour D et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001: 47: 1241.
19. Cattaneo D, Gaspari F, Ferrari S et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001: 15: 402.
20. Van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: A population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006: 17: 871.
21. Hesselink DA, van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin Pharmacol Ther 2005: 78: 317.